Non-peptide
PP405
Also known as
PP-405 · PP 405 · Pelage PP405 · MPC inhibitor hair gel
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
What it is
| Identity | Pelage's experimental scalp gel for hair regrowth, targeting the mitochondrial pyruvate carrier to change follicle-stem-cell metabolism. It is a small molecule, not a peptide or DHT blocker. |
|---|---|
| Outside products differ | The inspected diaries concern JXL069 or 3HP products. Names and claims about ester conversion do not establish equivalence to the clinical PP405 gel. |
Notes
PP405 is Pelage's experimental scalp gel for hair regrowth. The inspected diaries concern outside JXL069 or 3HP products. People describe better existing hair, fine new hairs, no meaningful change, or shedding severe enough to stop. Those accounts cannot establish how the clinical gel performs.
A topical small molecule, not injected stem cells. The intended target is the mitochondrial pyruvate carrier: a gate moving cellular fuel into mitochondria, the cell's energy machinery. Blocking that gate changes metabolism in follicle stem cells, with the aim of restarting growth. It is not a peptide or a DHT-blocking drug. When Chemistry and Biochemistry Meet the Marketplace (Official context · Accessed 2026-09-30)
Names do not authenticate a formulation. JXL069 and suvomipic feature in identity arguments. 3HP is discussed as a modified ester intended to release JXL069. Forum confidence does not establish conversion or equivalence to Pelage's gel. PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30)
Source context — When Chemistry and Biochemistry Meet the Marketplace: University commercialization feature, not a controlled results paper. Promotional safety and regrowth wording not adopted. No systemic safety guarantee or clinical half-life inferred.
Source context — PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing: One author's small-group summary; claimed lab testing and compound identity not audited. Other medicines, variable vehicles and lack of controlled counts. Title's confirmed identity, nocebo dismissal, safety and biochemical assertions are not accepted as established facts. Exact post date absent; body displayed two months ago.
What people notice
| Existing hair and fine hairs | One JXL069 commenter thought existing hair grew better without new growth. Two 3HP replies describe fine hairs without useful cosmetic improvement. |
|---|---|
| No meaningful change | Early reports include no regrowth; a raw-JXL069 tester reported no meaningful result after twelve weeks and further observation after stopping. That does not determine the clinical gel's performance. |
| Shedding and stopping | Some 3HP users describe more shedding or recession, including distress severe enough to stop. A hopeful week-eleven update later became a stopping report. |
Notes
Tiny hairs may not restore coverage. People hope for visible hair in thinning areas. One JXL069 commenter thought existing hair grew better without new growth. Two 3HP replies describe fine hairs without useful cosmetic improvement; these are not necessarily mature, thick hairs. Those using JXL069 (Community discussion · Accessed 2026-09-30) · PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30)
Quiet starts and early shedding both appear. Two JXL069 commenters reported no regrowth or side effects at days 5 and 11. A different commenter reported shedding at three weeks, later reporting no benefit. The day-11 author later described better existing hair, without new growth. Those using JXL069 (Community discussion · Accessed 2026-09-30)
No reliable lasting-growth window. A raw-JXL069 tester reported no meaningful result after 12 weeks and another couple of observation months after stopping. Their later 3HP experiment also disappointed. This is one author's small-group account, not independently documented failures. PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30)
PP405 is Pelage's experimental scalp gel for hair regrowth. The inspected diaries concern outside JXL069 or 3HP products. People describe better existing hair, fine new hairs, no meaningful change, or shedding severe enough to stop. Those accounts cannot establish how the clinical gel performs.
A hopeful update can end in disappointment. At week 11, a 3HP author described growth alongside continued shedding. A separate once-daily commenter reported more shedding and recession at week five. The hopeful author's later stopping report belongs to this same timeline. Week 11 Update Jxl069-3hp(pp405 replica) (Personal report · Accessed 2026-09-30) · Jxl069-3hp Update (Personal report · Accessed 2026-09-30)
Shedding eased after discontinuation in one account. The week-11 author stopped because shedding became distressing; it stopped shortly afterward. They did not know whether it would otherwise have settled. Retained regrowth and a precise recovery interval were not established. Jxl069-3hp Update (Personal report · Accessed 2026-09-30)
Shedding is not proof of eventual regrowth. MAD3SS returned after a week-five nonresponse to say thinning led them to stop at six or seven weeks. The main diary author's distress affected going outside. Neither account proves the cause, but neither supports treating every shed as a reassuring growth signal. Jxl069-3hp Update (Personal report · Accessed 2026-09-30) · Week 11 Update Jxl069-3hp(pp405 replica) (Personal report · Accessed 2026-09-30)
Source context — Those using JXL069: Uncontrolled outside solutions; concentrations absent from cited volume comments. Deleted author's attribution cannot be recovered. Concurrent dutasteride or multi-drug stacks differ. Photos and hidden replies were not independently assessed. About seven months old in displayed relative timestamps; exact publication date unavailable in opened body.
Source context — PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing: One author's small-group summary; claimed lab testing and compound identity not audited. Other medicines, variable vehicles and lack of controlled counts. Title's confirmed identity, nocebo dismissal, safety and biochemical assertions are not accepted as established facts. Exact post date absent; body displayed two months ago.
Source context — Week 11 Update Jxl069-3hp(pp405 replica): Outside ester, continuing co-treatments and unstandardized pictures. The photo content itself was not visually verified. Same author as the later stopping update. Exact date not supplied by opened body.
Source context — Jxl069-3hp Update: Same gtcyorktown timeline as week11. Dates shown in initial indexed full-thread result; reopened body uses relative age. Improvement in shedding after stopping has no exact interval or causal control. Subsequent added compounds further confound later hair history; no recipe or endorsement retained.
Doses people talk about
| Clinical gel context | The formal study used 0.05% scalp gel once daily for 28 days, with follow-up through day 84. This is a trial formulation and study design, not an outside-product dose. |
|---|---|
| JXL069 volumes | One commenter reported 1 mL daily and planned 0.75 mL. Another reported 0.5–0.75 mL per application six times weekly. Their unstated concentrations prevent calculation of milligrams. |
| 3HP applications | One author who eventually stopped confirmed once-daily scalp use. The account does not establish an equivalent PP405 amount or combination safety. |
Notes
The trial concentration is a formal value. NCT06393452 used 0.05% scalp gel once daily for 28 days, with follow-up through day 84. Twenty former vehicle recipients entered an 84-day active-gel extension. Those blocks are study designs, not DIY cycles. NCT06393452 posted study results and design (Official context · Accessed 2026-09-30)
Volume without concentration leaves the drug amount unknown. One JXL069 commenter reported 1 mL daily and planned 0.75 mL. Another reported 0.5–0.75 mL per application six times weekly. Their concentrations were not stated in those comments, so milligrams cannot be calculated. These are scalp solutions, not oral or injectable amounts. Those using JXL069 (Community discussion · Accessed 2026-09-30)
3HP diaries also include once-daily use. The author who eventually stopped confirmed once-daily application. Older discussion describes evenings around morning minoxidil and waiting for layers to dry, without establishing effectiveness or combination safety. Jxl069-3hp Update (Personal report · Accessed 2026-09-30)
Names do not authenticate a formulation. JXL069 and suvomipic feature in identity arguments. 3HP is discussed as a modified ester intended to release JXL069. Forum confidence does not establish conversion or equivalence to Pelage's gel. PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30)
Source context — NCT06393452 posted study results and design: Sponsor-submitted public registry results, not independent validation. Posted22 outcome tables concern safety and blood concentration; no efficacy density table. Concentrations coded zero at selected two-hour samples do not prove zero exposure at all times, give assay sensitivity or estimate half-life. Events are not automatically treatment-related. This is formal context only.
Source context — Those using JXL069: Uncontrolled outside solutions; concentrations absent from cited volume comments. Deleted author's attribution cannot be recovered. Concurrent dutasteride or multi-drug stacks differ. Photos and hidden replies were not independently assessed. About seven months old in displayed relative timestamps; exact publication date unavailable in opened body.
Source context — Jxl069-3hp Update: Same gtcyorktown timeline as week11. Dates shown in initial indexed full-thread result; reopened body uses relative age. Improvement in shedding after stopping has no exact interval or causal control. Subsequent added compounds further confound later hair history; no recipe or endorsement retained.
Source context — PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing: One author's small-group summary; claimed lab testing and compound identity not audited. Other medicines, variable vehicles and lack of controlled counts. Title's confirmed identity, nocebo dismissal, safety and biochemical assertions are not accepted as established facts. Exact post date absent; body displayed two months ago.
Half-life, onset & duration
| Felt or visible onset | No regrowth at days 5 or 11 in early JXL069 accounts; a separate user reported shedding at three weeks. A 3HP week-eleven growth impression coexisted with continued shedding. |
|---|---|
| Duration after stopping | Retained regrowth and a reliable benefit window are unknown. One author's shedding stopped shortly after discontinuation, without a precise recovery interval. |
| Half-life | No measured human half-life is established in these accounts. Claims about blood instability and selected two-hour blood samples do not establish scalp residence or clearance. |
Notes
Quiet starts and early shedding both appear. Two JXL069 commenters reported no regrowth or side effects at days 5 and 11. A different commenter reported shedding at three weeks, later reporting no benefit. The day-11 author later described better existing hair, without new growth. Those using JXL069 (Community discussion · Accessed 2026-09-30)
A hopeful update can end in disappointment. At week 11, a 3HP author described growth alongside continued shedding. A separate once-daily commenter reported more shedding and recession at week five. The hopeful author's later stopping report belongs to this same timeline. Week 11 Update Jxl069-3hp(pp405 replica) (Personal report · Accessed 2026-09-30) · Jxl069-3hp Update (Personal report · Accessed 2026-09-30)
No reliable lasting-growth window. A raw-JXL069 tester reported no meaningful result after 12 weeks and another couple of observation months after stopping. Their later 3HP experiment also disappointed. This is one author's small-group account, not independently documented failures. PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30)
Shedding eased after discontinuation in one account. The week-11 author stopped because shedding became distressing; it stopped shortly afterward. They did not know whether it would otherwise have settled. Retained regrowth and a precise recovery interval were not established. Jxl069-3hp Update (Personal report · Accessed 2026-09-30)
No measured human half-life in these accounts. A thread claims rapid instability in blood without a numerical human measurement. Blood concentration halving, scalp residence and time until visible hair growth are different clocks. PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30)
Blood samples do not give a half-life. Selected two-hour post-application samples were coded zero. This does not supply a half-life or exclude exposure at other times. Posted tables cover safety and blood concentrations, without a hair-density efficacy table. NCT06393452 posted study results and design (Official context · Accessed 2026-09-30)
Source context — Those using JXL069: Uncontrolled outside solutions; concentrations absent from cited volume comments. Deleted author's attribution cannot be recovered. Concurrent dutasteride or multi-drug stacks differ. Photos and hidden replies were not independently assessed. About seven months old in displayed relative timestamps; exact publication date unavailable in opened body.
Source context — Week 11 Update Jxl069-3hp(pp405 replica): Outside ester, continuing co-treatments and unstandardized pictures. The photo content itself was not visually verified. Same author as the later stopping update. Exact date not supplied by opened body.
Source context — Jxl069-3hp Update: Same gtcyorktown timeline as week11. Dates shown in initial indexed full-thread result; reopened body uses relative age. Improvement in shedding after stopping has no exact interval or causal control. Subsequent added compounds further confound later hair history; no recipe or endorsement retained.
Source context — PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing: One author's small-group summary; claimed lab testing and compound identity not audited. Other medicines, variable vehicles and lack of controlled counts. Title's confirmed identity, nocebo dismissal, safety and biochemical assertions are not accepted as established facts. Exact post date absent; body displayed two months ago.
Source context — NCT06393452 posted study results and design: Sponsor-submitted public registry results, not independent validation. Posted22 outcome tables concern safety and blood concentration; no efficacy density table. Concentrations coded zero at selected two-hour samples do not prove zero exposure at all times, give assay sensitivity or estimate half-life. Events are not automatically treatment-related. This is formal context only.
Cycles people discuss
| One planned break | After twelve weeks of 3HP, one user planned a month off while continuing long-term finasteride/minoxidil. Borrowing the trial's short block did not establish a repeat cycle. |
|---|---|
| Maintenance unknown | Staying on, stopping for shedding and retrying another vehicle are competing ideas. The records establish neither a maintenance calendar nor whether breaks preserve gains. |
Notes
A month off was one person's experiment. After 12 weeks of 3HP, Mobile_Jealous planned a month off while continuing five-year finasteride/minoxidil use. Their rationale borrowed the trial's short treatment block and misrecalled its assessment day. This does not establish a repeat cycle. Pp405 3hp 12 week update (Personal report · Accessed 2026-09-30)
No established maintenance calendar. Discussion includes stay-on-like-minoxidil speculation, stopping for shedding, and plans to retry with another vehicle. These competing ideas do not establish whether ongoing use is necessary or breaks preserve gains. PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30) · Jxl069-3hp Update (Personal report · Accessed 2026-09-30)
Source context — Pp405 3hp 12 week update: Outside ester and concurrent established treatments; no visual image assessment. Planned break is not a documented successful cycle. The author's day80 recollection conflicts with sponsor's week8 report. Exact publication date unavailable in opened body.
Source context — PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing: One author's small-group summary; claimed lab testing and compound identity not audited. Other medicines, variable vehicles and lack of controlled counts. Title's confirmed identity, nocebo dismissal, safety and biochemical assertions are not accepted as established facts. Exact post date absent; body displayed two months ago.
Source context — Jxl069-3hp Update: Same gtcyorktown timeline as week11. Dates shown in initial indexed full-thread result; reopened body uses relative age. Improvement in shedding after stopping has no exact interval or causal control. Subsequent added compounds further confound later hair history; no recipe or endorsement retained.
Stacks
| Existing hair-loss treatments | Minoxidil and finasteride continued during some diaries; dutasteride is also discussed. Those treatments prevent a clear outside-product-only comparison. |
|---|---|
| Experimental additions | GT20029 combination hopes and AHK-Cu/GHK-Cu mixed into the same dropper appear. These reports do not establish synergy, stability or combination safety. |
Notes
Photo readers disagree about meaningful progress. The 12-week 3HP thread includes praise, subtle-texture interpretations and objections about lighting and angle. The author remained on finasteride/minoxidil. The older record also mentions dutasteride, copper-peptide mixes and GT20029 combination hopes; these do not establish which ingredient helped or that a combination works. Pp405 3hp 12 week update (Personal report · Accessed 2026-09-30)
+ Minoxidil: Complementary-mechanism pitch. [community]
Finasteride or dutasteride: Concurrent treatment appears in the discussion and complicates attribution. A different proposed mechanism does not establish added benefit. [community]
Formulation comfort and biological effect are different questions. An early JXL069 user said the solution absorbed well while reporting no regrowth. Older notes raise vehicle irritation and uncertain stability. GHK-Cu or AHK-Cu in the same dropper adds another attribution problem. A pleasant application, changed texture or an impressive name does not verify effectiveness. Those using JXL069 (Community discussion · Accessed 2026-09-30)
GT20029: Proposed combination benefits remain speculation; no combination trial was located in the reviewed record. [community]
AHK-Cu or GHK-Cu: The older notes mention copper peptides in the same dropper. Multiple ingredients prevent isolated attribution and do not establish stability or safety. [anecdote]
3HP diaries also include once-daily use. The author who eventually stopped confirmed once-daily application. Older discussion describes evenings around morning minoxidil and waiting for layers to dry, without establishing effectiveness or combination safety. Jxl069-3hp Update (Personal report · Accessed 2026-09-30)
Source context — Pp405 3hp 12 week update: Outside ester and concurrent established treatments; no visual image assessment. Planned break is not a documented successful cycle. The author's day80 recollection conflicts with sponsor's week8 report. Exact publication date unavailable in opened body.
Source context — Those using JXL069: Uncontrolled outside solutions; concentrations absent from cited volume comments. Deleted author's attribution cannot be recovered. Concurrent dutasteride or multi-drug stacks differ. Photos and hidden replies were not independently assessed. About seven months old in displayed relative timestamps; exact publication date unavailable in opened body.
Source context — Jxl069-3hp Update: Same gtcyorktown timeline as week11. Dates shown in initial indexed full-thread result; reopened body uses relative age. Improvement in shedding after stopping has no exact interval or causal control. Subsequent added compounds further confound later hair history; no recipe or endorsement retained.
Watch for
| Distressing shedding | Shedding is not proof of eventual regrowth. One user stopped at six or seven weeks after thinning; another described distress affecting going outside. |
|---|---|
| Local reactions | The posted clinical table includes itching, redness and pain; itching occurred in 7/51 active-gel and 2/27 vehicle participants. Events need not be drug-caused or predict outside-product safety. |
| Identity and long-term gaps | The saved Pelage record describes PP405 as investigational and not approved for sale. Outside-product identity, long-term effects, interactions and pregnancy safety remain unresolved here. |
Notes
Shedding is not proof of eventual regrowth. MAD3SS returned after a week-five nonresponse to say thinning led them to stop at six or seven weeks. The main diary author's distress affected going outside. Neither account proves the cause, but neither supports treating every shed as a reassuring growth signal. Jxl069-3hp Update (Personal report · Accessed 2026-09-30) · Week 11 Update Jxl069-3hp(pp405 replica) (Personal report · Accessed 2026-09-30)
The clinical safety table now exists. Results posted September 22, 2026 include local itching, redness and pain. Itching affected 7/51 active-gel participants and 2/27 vehicle participants. Events need not be drug-caused; short follow-up cannot establish long-term or outside-product safety. NCT06393452 posted study results and design (Official context · Accessed 2026-09-30)
A trial claim cannot certify a shop product. Pelage still describes PP405 as investigational and not FDA-approved for sale. The original record's concern about unknown outside identity remains useful; claims that every shop bottle contains an ester or that all symptoms are nocebo go beyond the evidence. Pelage terms of use (Official context · Accessed 2026-09-30) · PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (Personal report · Accessed 2026-09-30)
Women's hopes exceed the diary evidence. The older record notes mostly male diaries despite hopes of usefulness for women. These accounts cannot establish effects across hair-loss causes or settle pregnancy, interaction and long-term safety questions.
Source context — Jxl069-3hp Update: Same gtcyorktown timeline as week11. Dates shown in initial indexed full-thread result; reopened body uses relative age. Improvement in shedding after stopping has no exact interval or causal control. Subsequent added compounds further confound later hair history; no recipe or endorsement retained.
Source context — Week 11 Update Jxl069-3hp(pp405 replica): Outside ester, continuing co-treatments and unstandardized pictures. The photo content itself was not visually verified. Same author as the later stopping update. Exact date not supplied by opened body.
Source context — NCT06393452 posted study results and design: Sponsor-submitted public registry results, not independent validation. Posted22 outcome tables concern safety and blood concentration; no efficacy density table. Concentrations coded zero at selected two-hour samples do not prove zero exposure at all times, give assay sensitivity or estimate half-life. Events are not automatically treatment-related. This is formal context only.
Source context — Pelage terms of use: Sponsor website terms, not a comprehensive regulator search; phase wording may lag program progress. Article avoids claiming a current Phase3 start or future launch date.
Source context — PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing: One author's small-group summary; claimed lab testing and compound identity not audited. Other medicines, variable vehicles and lack of controlled counts. Title's confirmed identity, nocebo dismissal, safety and biochemical assertions are not accepted as established facts. Exact post date absent; body displayed two months ago.
Full notes
PP405 is Pelage's experimental scalp gel for hair regrowth. The inspected diaries concern outside JXL069 or 3HP products. People describe better existing hair, fine new hairs, no meaningful change, or shedding severe enough to stop. Those accounts cannot establish how the clinical gel performs.
What is behind the follicle-waking idea
- A topical small molecule, not injected stem cells. The intended target is the mitochondrial pyruvate carrier: a gate moving cellular fuel into mitochondria, the cell's energy machinery. Blocking that gate changes metabolism in follicle stem cells, with the aim of restarting growth. It is not a peptide or a DHT-blocking drug. Official context Community
- Names do not authenticate a formulation. JXL069 and suvomipic feature in identity arguments. 3HP is discussed as a modified ester intended to release JXL069. Forum confidence does not establish conversion or equivalence to Pelage's gel. Personal report Community
What people want to get back
- Tiny hairs may not restore coverage. People hope for visible hair in thinning areas. One JXL069 commenter thought existing hair grew better without new growth. Two 3HP replies describe fine hairs without useful cosmetic improvement; these are not necessarily mature, thick hairs. Reddit / r/HairlossResearch Personal report Community
- Hope spreads beyond hair-loss forums. An Eroids discussion includes optimism, future-cost concern and skepticism. One poster hoped it might help their wife's hair after childbirth. These are hopes, not treatment experiences or evidence for that cause of hair loss. Eroids bodybuilding forum
Amounts and application frequency people report
These are outside-product accounts, not directions for use.
- Volume without concentration leaves the drug amount unknown. One JXL069 commenter reported 1 mL daily and planned 0.75 mL. Another reported 0.5–0.75 mL per application six times weekly. Their concentrations were not stated in those comments, so milligrams cannot be calculated. These are scalp solutions, not oral or injectable amounts. Reddit / r/HairlossResearch
- 3HP diaries also include once-daily use. The author who eventually stopped confirmed once-daily application. Older discussion describes evenings around morning minoxidil and waiting for layers to dry, without establishing effectiveness or combination safety. Personal report Community
What the half-life discussion can tell us
- No measured human half-life in these accounts. A thread claims rapid instability in blood without a numerical human measurement. Blood concentration halving, scalp residence and time until visible hair growth are different clocks. Personal report
When changes first enter the diaries
- Quiet starts and early shedding both appear. Two JXL069 commenters reported no regrowth or side effects at days 5 and 11. A different commenter reported shedding at three weeks, later reporting no benefit. The day-11 author later described better existing hair, without new growth. Reddit / r/HairlossResearch
- A hopeful update can end in disappointment. At week 11, a 3HP author described growth alongside continued shedding. A separate once-daily commenter reported more shedding and recession at week five. The hopeful author's later stopping report belongs to this same timeline. Personal report Personal report
Persistence and what happened after stopping
- No reliable lasting-growth window. A raw-JXL069 tester reported no meaningful result after 12 weeks and another couple of observation months after stopping. Their later 3HP experiment also disappointed. This is one author's small-group account, not independently documented failures. Personal report
- Shedding eased after discontinuation in one account. The week-11 author stopped because shedding became distressing; it stopped shortly afterward. They did not know whether it would otherwise have settled. Retained regrowth and a precise recovery interval were not established. Personal report
Breaks, continued use and retry talk
- A month off was one person's experiment. After 12 weeks of 3HP, Mobile_Jealous planned a month off while continuing five-year finasteride/minoxidil use. Their rationale borrowed the trial's short treatment block and misrecalled its assessment day. This does not establish a repeat cycle. Personal report
- No established maintenance calendar. Discussion includes stay-on-like-minoxidil speculation, stopping for shedding, and plans to retry with another vehicle. These competing ideas do not establish whether ongoing use is necessary or breaks preserve gains. Community Personal report Personal report
What complicates the hopeful accounts
- Shedding is not proof of eventual regrowth. MAD3SS returned after a week-five nonresponse to say thinning led them to stop at six or seven weeks. The main diary author's distress affected going outside. Neither account proves the cause, but neither supports treating every shed as a reassuring growth signal. Personal report Personal report
- The clinical safety table now exists. Results posted September 22, 2026 include local itching, redness and pain. Itching affected 7/51 active-gel participants and 2/27 vehicle participants. Events need not be drug-caused; short follow-up cannot establish long-term or outside-product safety. Official context
- A trial claim cannot certify a shop product. Pelage still describes PP405 as investigational and not FDA-approved for sale. The original record's concern about unknown outside identity remains useful; claims that every shop bottle contains an ester or that all symptoms are nocebo go beyond the evidence. Official context Community Personal report
- Women's hopes exceed the diary evidence. The older record notes mostly male diaries despite hopes of usefulness for women. These accounts cannot establish effects across hair-loss causes or settle pregnancy, interaction and long-term safety questions. Community
What the full accounts add
- Vehicle questions survive a negative result. The raw-JXL069 tester asserted third-party testing, varied group vehicles and acknowledged other medicines. They remained skeptical but planned another formulation attempt. This account neither certifies the ingredients nor rules out the clinical gel. Personal report
- Photo readers disagree about meaningful progress. The 12-week 3HP thread includes praise, subtle-texture interpretations and objections about lighting and angle. The author remained on finasteride/minoxidil. The older record also mentions dutasteride, copper-peptide mixes and GT20029 combination hopes; these do not establish which ingredient helped or that a combination works. Personal report Community
- Formulation comfort and biological effect are different questions. An early JXL069 user said the solution absorbed well while reporting no regrowth. Older notes raise vehicle irritation and uncertain stability. GHK-Cu or AHK-Cu in the same dropper adds another attribution problem. A pleasant application, changed texture or an impressive name does not verify effectiveness. Reddit / r/HairlossResearch Community
Separate clinical context behind the circulating numbers
- The trial concentration is a formal value. NCT06393452 used 0.05% scalp gel once daily for 28 days, with follow-up through day 84. Twenty former vehicle recipients entered an 84-day active-gel extension. Those blocks are study designs, not DIY cycles. Official context
- 31% describes responders within a male subgroup. Pelage reported that at week eight, 31% of men with greater hair loss exceeded a 20% density increase, versus 0% with vehicle. It is not a 31% average gain. Circulated terminal-versus-fine-hair slide claims remain company claims, not confirmed community outcomes. Official context Community
- Blood samples do not give a half-life. Selected two-hour post-application samples were coded zero. This does not supply a half-life or exclude exposure at other times. Posted tables cover safety and blood concentrations, without a hair-density efficacy table. Official context